Skip to content


BMC Cancer

What do you think about BMC? Take part in

Call for papers: The Advances of CAR Immunotherapy within Oncology Clinics

New Content ItemBMC Cancer and BMC Biotechnology are delighted to announce the launch of a new cross-journal thematic series focused on the emerging field of Chimeric Antigen Receptor (CAR) Immunotherapy, which will review and feature the role of synthetic biology and gene engineering in CAR Immunotherapy, but also the advances of CAR Immunotherapy within oncology clinics.

Featured blog: Systematic reviews made simple

New Content ItemBMC Cancer recently published a systematic review of previous systematic reviews with statistical analyses and meta-analyses, regarding the effects of exercise on cancer-related-fatigue in adult cancer patients and survivors. In this blog, Prof. George Kelley, Director of the Meta-Analytic Research Group at West Virginia University, discusses more about his approach and the associated challenges.

Featured video: Microparticles, breast cancer's secret weapon?

Read the article


View all articles
View all articles

Aims and scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.


Consulting Editors

Alan Lefor, Consulting Editor

Alan Kawarai Lefor is Professor of Surgery at Jichi Medical University in Tochigi, Japan. He is the author of over 500 publications and 12 textbooks in English and Japanese. He joined BMC Cancer as a Deputy Section Editor in 2014 and has been serving as Consulting Editor since 2017.

Latest Tweets


2016 Journal Metrics